USA - NASDAQ:COO - US2166485019 - Common Stock
The current stock price of COO is 72.3515 USD. In the past month the price increased by 5.42%. In the past year, price decreased by -27.24%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SOLV | SOLVENTUM CORP | 12.68 | 13.06B | ||
| ALGN | ALIGN TECHNOLOGY INC | 14.51 | 10.17B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 23.6 | 5.20B | ||
| LNTH | LANTHEUS HOLDINGS INC | 9.08 | 3.68B | ||
| HAE | HAEMONETICS CORP/MASS | 15.45 | 3.57B | ||
| ICUI | ICU MEDICAL INC | 17.49 | 3.44B | ||
| XRAY | DENTSPLY SIRONA INC | 6.97 | 2.20B | ||
| UFPT | UFP TECHNOLOGIES INC | 27.1 | 1.80B | ||
| NEOG | NEOGEN CORP | 21.45 | 1.40B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.29B | ||
| EMBC | EMBECTA CORP | 5.02 | 856.88M | ||
| BVS | BIOVENTUS INC - A | 12.75 | 621.75M |
The Cooper Cos, Inc. operates as a medical device company. The company is headquartered in San Ramon, California and currently employs 16,000 full-time employees. The firm operates in two business units: CooperVision and CooperSurgical. CooperVision segment is involved in the contact lens industry. CooperSurgical segment is involved in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgical’s portfolio includes INSORB, Lone Star, and the Doppler Blood Flow Monitor. The company also offers a suite of single-use cordless surgical retractors with an integrated multi-light-emitting diode (LED) light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source.
COOPER COS INC/THE
6101 Bollinger Canyon Road, Suite 500
San Ramon CALIFORNIA 94583 US
CEO: Albert G. White III
Employees: 16000
Phone: 19254603600
The Cooper Cos, Inc. operates as a medical device company. The company is headquartered in San Ramon, California and currently employs 16,000 full-time employees. The firm operates in two business units: CooperVision and CooperSurgical. CooperVision segment is involved in the contact lens industry. CooperSurgical segment is involved in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgical’s portfolio includes INSORB, Lone Star, and the Doppler Blood Flow Monitor. The company also offers a suite of single-use cordless surgical retractors with an integrated multi-light-emitting diode (LED) light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source.
The current stock price of COO is 72.3515 USD. The price decreased by -0.19% in the last trading session.
COOPER COS INC/THE (COO) has a dividend yield of 0.02%. The yearly dividend amount is currently 0.
COO has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
The PE ratio for COOPER COS INC/THE (COO) is 18. This is based on the reported non-GAAP earnings per share of 4.02 and the current share price of 72.3515 USD.
The Revenue of COOPER COS INC/THE (COO) is expected to grow by 4.74% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
COOPER COS INC/THE (COO) currently has 16000 employees.
ChartMill assigns a technical rating of 4 / 10 to COO. When comparing the yearly performance of all stocks, COO is a bad performer in the overall market: 82.55% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to COO. COO has an excellent profitability rating, but there are some minor concerns on its financial health.
Over the last trailing twelve months COO reported a non-GAAP Earnings per Share(EPS) of 4.02. The EPS increased by 13.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.08% | ||
| ROA | 3.29% | ||
| ROE | 4.88% | ||
| Debt/Equity | 0.3 |
25 analysts have analysed COO and the average price target is 85.47 USD. This implies a price increase of 18.14% is expected in the next year compared to the current price of 72.3515.
For the next year, analysts expect an EPS growth of 11.8% and a revenue growth 4.74% for COO